Multiple studies have investigated the potential of radiomics in predicting grade II-III glioma IDH-mutation status before and after the recent reclassifications by the WHO in 2016 and 2021 [92,93,94,95,96,97,98]. Here, IDH1 is linked to central nervous system cancer.